We also employed another preclinical model of GBM (CT2A) that is resistant to αPD1 and has a lower mutational burden27, specifically without IDH1-R132H mutation28 that may contribute to reduced Treg cell presence in GBM29. The gene discussed is IDH1; the disease is glioblastoma.